Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert
03:15pm, Tuesday, 21'st Jan 2025
Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence.
What's next for Viking Therapeutics? Here's how the company can scale up.
03:04pm, Tuesday, 21'st Jan 2025
Viking's obesity-drug program is progressing well. Now management is thinking about manufacturing tie-ups.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
10:36am, Monday, 20'th Jan 2025
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
12:00pm, Saturday, 18'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
11:37am, Friday, 17'th Jan 2025
A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of companies selling (or hoping to sell) semaglutide and related drugs for treatin
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
08:45pm, Thursday, 16'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
02:31pm, Wednesday, 15'th Jan 2025
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
09:04pm, Tuesday, 14'th Jan 2025
NEW YORK , Jan. 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are ad
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
12:11pm, Tuesday, 14'th Jan 2025
Bad news for Eli Lilly (LLY -7.38%) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday. Lilly updated investors on its expected revenue for 2024 this morning, a
3 Oversold Biotech Names
12:56pm, Monday, 13'th Jan 2025
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
12:00pm, Friday, 10'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are a
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
07:21am, Thursday, 09'th Jan 2025
The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.
3 Mid-Cap Stocks That Could Take Off in 2025
04:20am, Thursday, 09'th Jan 2025
Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more modest valuations. Mid-cap stocks represent companies valued at between $2
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
12:00pm, Wednesday, 08'th Jan 2025
NEW YORK , Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are adv
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
07:03am, Wednesday, 08'th Jan 2025
13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biophar
